Prognosis after resection of single large hepatocellular carcinoma: Results from an Asian high-volume liver surgery center.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
30
01
2020
accepted:
11
03
2020
entrez:
29
3
2020
pubmed:
29
3
2020
medline:
1
7
2020
Statut:
epublish
Résumé
In 2012, the Barcelona Clinic Liver Cancer (BCLC) system designated a single large hepatocellular carcinoma (SLHCC) (>5 cm) as BCLC stage A rather than stage B. However, a recent study from western countries reported that prognosis following liver resection (LR) among patients with SLHCC was similar to that among patients with BCLC stage B. We aim to evaluate the prognosis following LR among patients with SLHCC from an Asian high-volume liver surgery center. Patients who underwent curative-intent LR for histologically proven HCC between 2011 and 2017 were enrolled using an HCC registry database. Overall survival (OS) among patients with BCLC stages 0, A, and B was examined. Patients with a SLHCC were classified as BCLC stage A1. Among 543 patients, 89 (16.4%) were BCLC stage 0, 289 (53.2%) were BCLC stage A, 92 (16.9%) were BCLC stage A1, and 73 (13.4%) were BCLC stage B. The median follow-up was 38 months. The five-year OS rates among patients with BCLC stages 0, A, A1, and B were 83.5%, 83.7%, 77.4%, and 55.4%, respectively (p<0.001). No difference in OS was noted for patients with BCLC stage A versus A1 (p = 0.11), even after adjusting for competing factors (hazard ratio = 0.97, 95% confidence interval = 0.53-1.79; p = 0.93). Prognosis following LR among patients with SLHCC was similar to that among patients with BCLC stage A. The prognosis for SLHCC should thus be considered comparable to that for BCLC stage A.
Sections du résumé
BACKGROUND & AIMS
In 2012, the Barcelona Clinic Liver Cancer (BCLC) system designated a single large hepatocellular carcinoma (SLHCC) (>5 cm) as BCLC stage A rather than stage B. However, a recent study from western countries reported that prognosis following liver resection (LR) among patients with SLHCC was similar to that among patients with BCLC stage B. We aim to evaluate the prognosis following LR among patients with SLHCC from an Asian high-volume liver surgery center.
METHODS
Patients who underwent curative-intent LR for histologically proven HCC between 2011 and 2017 were enrolled using an HCC registry database. Overall survival (OS) among patients with BCLC stages 0, A, and B was examined. Patients with a SLHCC were classified as BCLC stage A1.
RESULTS
Among 543 patients, 89 (16.4%) were BCLC stage 0, 289 (53.2%) were BCLC stage A, 92 (16.9%) were BCLC stage A1, and 73 (13.4%) were BCLC stage B. The median follow-up was 38 months. The five-year OS rates among patients with BCLC stages 0, A, A1, and B were 83.5%, 83.7%, 77.4%, and 55.4%, respectively (p<0.001). No difference in OS was noted for patients with BCLC stage A versus A1 (p = 0.11), even after adjusting for competing factors (hazard ratio = 0.97, 95% confidence interval = 0.53-1.79; p = 0.93).
CONCLUSION
Prognosis following LR among patients with SLHCC was similar to that among patients with BCLC stage A. The prognosis for SLHCC should thus be considered comparable to that for BCLC stage A.
Identifiants
pubmed: 32218593
doi: 10.1371/journal.pone.0230897
pii: PONE-D-20-02819
pmc: PMC7100934
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0230897Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Hepatology. 2010 Feb;51(2):585-94
pubmed: 20101752
Hepatology. 2009 Mar;49(3):851-9
pubmed: 19115377
J Gastrointest Surg. 2014 Nov;18(11):1994-2002
pubmed: 25213582
Int J Cancer. 2011 May 15;128(10):2436-43
pubmed: 21128245
Cancer. 1954 May;7(3):462-503
pubmed: 13160935
Aliment Pharmacol Ther. 2019 Oct;50(7):809-821
pubmed: 31475372
J Hepatol. 2012 Apr;56(4):908-43
pubmed: 22424438
Jpn J Radiol. 2014 Nov;32(11):644-9
pubmed: 25213426
PLoS One. 2016 Nov 15;11(11):e0165722
pubmed: 27846227
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
Ann Surg Oncol. 2019 Oct;26(11):3693-3700
pubmed: 31267302
J Gastroenterol Hepatol. 2016 Feb;31(2):467-74
pubmed: 26332049
Addiction. 1993 Jun;88(6):791-804
pubmed: 8329970
Eur J Surg Oncol. 2018 Jul;44(7):927-938
pubmed: 29751946
J Gastroenterol Hepatol. 2014 Apr;29(4):787-93
pubmed: 24224567
Hepatology. 2018 Aug;68(2):723-750
pubmed: 29624699
PLoS One. 2016 May 13;11(5):e0155588
pubmed: 27176037
Hepatology. 2015 Apr;61(4):1154-62
pubmed: 25476749
World J Gastroenterol. 2014 Mar 28;20(12):3335-42
pubmed: 24696614
J Hepatol. 2015 Mar;62(3):617-24
pubmed: 25450706
Br J Surg. 2015 Jun;102(7):776-84
pubmed: 25847111
J Clin Exp Hepatol. 2014 Aug;4(Suppl 3):S90-6
pubmed: 25755617
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Hepatology. 2016 Mar;63(3):827-38
pubmed: 26599351
Semin Liver Dis. 2012 Nov;32(4):348-59
pubmed: 23397536